| Literature DB >> 35734566 |
Luis Octavio Tierradentro-García1,2,3, María Camila Cortés-Albornoz2,3, Claudia Talero-Gutiérrez2,3.
Abstract
Human rabies has been described by various cultures in many countries around the world. Gabriel García Márquez's novel Of love and other demons recounts the story of a girl who, in colonial Colombia in the 18th century, was bitten by a rabid dog. This paper aims to review the general status of the disease in Colombia and interweave it with García Márquez's book. Developed countries have successfully controlled dog-mediated rabies virus transmission, whereas in some countries in Latin America wildlife and canine rabies are still an issue. Our approach suggests that although the measures that have been taken to mitigate dog-transmitted rabies have worked well in most parts of the world, greater efforts are required to control sylvatic rabies transmitted by bats or other mammals, as occurs in Colombia. Since developing countries are the most affected by the disease at present, transdisciplinary commitment between human and veterinary sectors is necessary to fight against rabies virus transmission.Entities:
Keywords: Colombia; Epidemiology; Human rabies; Literature; Rabies
Year: 2022 PMID: 35734566 PMCID: PMC9207665 DOI: 10.1016/j.heliyon.2022.e09703
Source DB: PubMed Journal: Heliyon ISSN: 2405-8440
Human deaths from rabies in Colombia in the current century†.
| Year | Regions [number deaths] | Number of deaths | Vector [number of deaths] |
|---|---|---|---|
| Putumayo [1] | 1 | Dog [1] | |
| Cundinamarca [1] | 1 | Cat [1] | |
| Chocó [14] | 14 | Bat [14] | |
| Chocó [3] | 3 | Dog [3] | |
| Magdalena [2] | 2 | Cat [2] | |
| Magdalena [2], Casanare [1] | 3 | Cat [2], bat [1] | |
| Cauca [3], Santander [1] | 4 | Cat [1], bat [3] | |
| Boyacá [1], Santander [1] | 2 | Cat [2] | |
| Tolima [1], Santander [2] | 3 | Cat [2], bat [1] | |
| Valle del Cauca [2] | 2 | Cat [2] | |
| Cundinamarca [2] | 1 | Cat [1] | |
| Cundinamarca [1] | 1 | Cat [1] | |
| Cundinamarca [1] | 1 | Cat [1] | |
| Huila [1] | 1 | Cat [1] | |
| Huila [1] | 1 | Cat [1] |
Data collected until April 2022. Table modified from Sánchez, M. del P., Díaz Sanchez, O. A., Sanmiguel, R. A., Ramirez, A. A., & Escobar, L. (2019). Rabia en las Américas, varios desafíos y « Una Sola Salud: Artículo de revisión. Revista de Investigaciones Veterinarias Del Perú, 30 (4), 1361–1381.
Figure 1Human rabies-related deaths in Colombia. (a) Graph represents cases of human rabies-related deaths over 21 years; note the peak in 2004. (b) Topographical map depicts number of cases per region. Red star = 14 cases (Chocó); orange stars = 4 cases (Magdalena, Santander, and Cundinamarca); yellow star = 3 cases (Cauca); blue star = 2 cases (Huila); green stars = 1 case (Boyacá, Casanare, Tolima, Putumayo, and Valle del Cauca). Of note, the map reveals that most cases occurred in the mountainous region and near the Pacific coast. Modified from https://geoportal.igac.gov.co/contenido/mapas-nacionales.
Current World Health Organization recommendations on rabies prophylaxis.
| WHO 2018 recommendations on rabies prophylaxis | ||||
|---|---|---|---|---|
| Exposure classification | Immediate action | Immunization schedules | Vaccine administration route | |
| Category I | Immunologically naive individuals: Wash exposed skin | None. | Intramuscular (IM) or intradermal (ID) route Adults and Children older than 2 years old: administration in the deltoid region Children younger than 2 years old: administration in the anterolateral thigh or suprascapular region. | |
| Category II | Wash exposed skin and vaccinate | 2-sites ID on days 0, 3 and 7. 1-site IM on days 0, 3, 7, and between days 14–28 2-sites IM on days 0 and 1-site IM on days 7, 21 1-site ID on days 0 and 3 at 4-sites ID on day 0 at 1-site IM on days 0 and 3 | ||
| Category III | Wash exposed skin, vaccinate and Rabies Immune Globulin administration if available (within 7 days from the start of vaccination) | 2-sites ID on days 0, 3 and 7 1-site IM on days 0, 3, 7, and between days 14–28 2-sites IM on days 0 and 1 site IM on days 7, 21 1-site ID on days 0 and 3 at 4-sites ID on day 0 at 1-site IM on days 0 and 3 | ||
| None, In all individuals with occupational high risk | Vaccination | 2 sites ID vaccine administration on days 0 and 7 1-site IM vaccine administration on days 0 and 7 | ||
WHO: World Health Organization; ID: intradermal; IM: intramuscular; PEP: post-exposure prophylaxis.